WAVE Life Sciences Ltd. (NASDAQ:WVE) will announce its earnings results on Monday, August 14th. Analysts expect the company to announce earnings of ($0.78) per share for the quarter.

WAVE Life Sciences (NASDAQ:WVE) last issued its quarterly earnings data on Wednesday, May 10th. The company reported ($0.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by $0.12. The firm had revenue of $0.68 million during the quarter, compared to the consensus estimate of $0.80 million. WAVE Life Sciences had a negative net margin of 3,172.14% and a negative return on equity of 48.16%. On average, analysts expect WAVE Life Sciences to post $-3.31 EPS for the current fiscal year and $-3.27 EPS for the next fiscal year.

Shares of WAVE Life Sciences Ltd. (NASDAQ WVE) opened at 20.10 on Monday. WAVE Life Sciences Ltd. has a 12 month low of $15.15 and a 12 month high of $40.15. The company has a 50-day moving average of $19.11 and a 200 day moving average of $23.57. The company’s market capitalization is $557.11 million.

ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.thecerbatgem.com/2017/08/07/wave-life-sciences-ltd-nasdaqwve-to-release-quarterly-earnings-on-monday.html.

In related news, insider Michael A. Panzara sold 7,414 shares of the company’s stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $16.67, for a total transaction of $123,591.38. Following the transaction, the insider now owns 15,336 shares in the company, valued at approximately $255,651.12. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 53.00% of the stock is currently owned by corporate insiders.

Several equities research analysts have issued reports on WVE shares. ValuEngine lowered shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Friday, June 16th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $42.00 target price on shares of WAVE Life Sciences in a report on Wednesday, April 26th. Zacks Investment Research lowered shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Finally, JMP Securities reaffirmed an “outperform” rating and issued a $40.00 target price on shares of WAVE Life Sciences in a report on Friday, June 9th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $42.00.

WAVE Life Sciences Company Profile

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Receive News & Stock Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related stocks with our FREE daily email newsletter.